These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 15816472)

  • 1. Oxidative stress in chronic hepatitis C: a preliminary study on the protective effects of antioxidant flavonoids.
    Emerit I; Huang CY; Serejo F; Filipe P; Fernandes A; Costa A; Freitas J; Baptista A; Carneiro de Moura M
    Hepatogastroenterology; 2005; 52(62):530-6. PubMed ID: 15816472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antiviral therapy of patients with chronic hepatitis C with normal level of aminotransferases].
    Lopukhova NL
    Eksp Klin Gastroenterol; 2007; (4):146-52. PubMed ID: 18409502
    [No Abstract]   [Full Text] [Related]  

  • 3. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The role and possibilities of natural interferon treatment in chronic hepatitis C: experience with natural interferon treatment for patients barred from combined antiviral therapy because of the STOP rule].
    Horváth G; Tolvaj G; Halász T; Stotz G
    Orv Hetil; 2007 Aug; 148(33):1545-50. PubMed ID: 17686672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antioxidant supplementation attenuates oxidative stress in chronic hepatitis C patients.
    Farias MS; Budni P; Ribeiro CM; Parisotto EB; Santos CE; Dias JF; Dalmarco EM; Fröde TS; Pedrosa RC; Wilhelm Filho D
    Gastroenterol Hepatol; 2012; 35(6):386-94. PubMed ID: 22608494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum alpha-foetoprotein level predicts treatment outcome in chronic hepatitis C.
    Males S; Gad RR; Esmat G; Abobakr H; Anwar M; Rekacewicz C; El Hoseiny M; Zalata K; Abdel-Hamid M; Bedossa P; Pol S; Mohamed MK; Fontanet A
    Antivir Ther; 2007; 12(5):797-803. PubMed ID: 17713163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels.
    Gerkens S; Nechelput M; Annemans L; Peraux B; Beguin C; Horsmans Y
    Acta Gastroenterol Belg; 2007; 70(2):177-87. PubMed ID: 17715631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pilot study of low-dose interleukin-2, pegylated interferon-alpha 2b, and ribavirin for the treatment of hepatitis C virus infection in patients with HIV infection.
    Glesby MJ; Bassett R; Alston-Smith B; Fichtenbaum C; Jacobson EL; Brass C; Owens S; Sulkowski M; Race EM; Sherman KE;
    J Infect Dis; 2005 Mar; 191(5):686-93. PubMed ID: 15688281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response.
    Kamal SM; El Tawil AA; Nakano T; He Q; Rasenack J; Hakam SA; Saleh WA; Ismail A; Aziz AA; Madwar MA
    Gut; 2005 Jun; 54(6):858-66. PubMed ID: 15888797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.
    Ferenci P; Formann E; Laferl H; Gschwantler M; Hackl F; Brunner H; Hubmann R; Datz C; Stauber R; Steindl-Munda P; Kessler HH; Klingler A; Gangl A;
    J Hepatol; 2006 Feb; 44(2):275-82. PubMed ID: 16338019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of interferon, ribavirin and ursodeoxycholic acid in patients with hepatitis C infection.
    Ljubuncic P; Konikoff FM; Blendis LM; Bomzon A
    Hepatogastroenterology; 2005; 52(64):1191-6. PubMed ID: 16001659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin.
    Asahina Y; Izumi N; Umeda N; Hosokawa T; Ueda K; Doi F; Tsuchiya K; Nakanishi H; Matsunaga K; Kitamura T; Kurosaki M; Uchihara M; Higaki M; Miyake S
    J Viral Hepat; 2007 Jun; 14(6):396-403. PubMed ID: 17501760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to pegylated interferon alpha-2b and ribavirin in children with chronic hepatitis C.
    Baker RD; Dee D; Baker SS
    J Clin Gastroenterol; 2007 Jan; 41(1):111-4. PubMed ID: 17198073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of pegylated interferon alpha 2b and ribavirin in chronic hepatitis C--a report from eastern India.
    Ray G; Pal S; Nayyar I; Dey S
    Trop Gastroenterol; 2007; 28(3):109-12. PubMed ID: 18383998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)].
    Pár A; Tornai I; Szalay F
    Orv Hetil; 2007 May; 148(18):819-26. PubMed ID: 17468063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, pharmacodynamics, and hepatitis C viral kinetics during antiviral therapy: the null responder.
    Di Bisceglie AM; Fan X; Chambers T; Strinko J
    J Med Virol; 2006 Apr; 78(4):446-51. PubMed ID: 16566033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tomato-based functional food as interferon adjuvant in HCV eradication therapy.
    Morisco F; Vitaglione P; Carbone A; Stingo S; Scarpati S; Ascione A; Marmo R; Fogliano V; Caporaso N
    J Clin Gastroenterol; 2004 Jul; 38(6 Suppl):S118-20. PubMed ID: 15220675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term management of hepatitis C-seropositive subjects with AntiOxidant Biofactor (AOB), a fermented food supplement.
    Myo-Khin ; Myat-Tin-Htwe-Kyaw ; Yi-Yi-Kyaw ; Ohmar-Lwin ; Myat-Phone-Kyaw ; Khin-May-Oo ; Shimono K; Koide N; Okada S
    Acta Med Okayama; 2010 Aug; 64(4):243-8. PubMed ID: 20802541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.